The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Outcomes and Cosmesis With Whole Breast Irradiation and Boost
Official Title: Patient-Reported Outcomes and Cosmesis Following Five Fraction Whole Breast Irradiation With Simultaneous Integrated Boost
Study ID: NCT06295744
Brief Summary: This study is being done to evaluate cosmetic, patient-reported outcome measures (PROMs), and toxicities for women undergoing ultra-short whole breast irradiation (WBI) therapy with simultaneous integrated boost (SIB). 50 participants will be on study for up to 60 months.
Detailed Description: The study population will consist of 50 participants with non-metastatic, early-stage invasive breast cancer or ductal carcinoma in situ (DCIS). Eligible patients will include those with a biopsy proven invasive breast cancer or DCIS, greater than or equal to 18 years of age, undergoing breast conserving surgery and adjuvant radiation therapy at UW Health with an indication for WBI with tumor bed boost. Selection need for boost and radiation treatment field design and pre-tx imaging are at the discretion of the treating provider. Accrual will occur over 5 years at UW Health. Participants will complete 5 treatment visits and 7 study visits over the course of approximately 5.5 years. Research-related outcome measures - MD assessments (e.g., cosmesis) PROMs, and AEs -- will be assessed prior to treatment start, at the 6-week follow-up visit, as well as at 12-, 24-, 36-, 48- and 60-month follow-up visits. Study participation ends after completion of the 60-month follow-up visit. Objective ⢠To assess two-year cosmetic outcomes in patients treated with ultra-short WBI with a SIB. Secondary Objectives * To assess PROMs via BREAST-Q in patients treated with ultra-short WBI with SIB. * To assess acute toxicities in patients treated with ultra-short WBI with SIB. * To assess late toxicities in patients treated with ultra-short WBI with SIB. * To assess ipsilateral breast tumor recurrence in patients treated with ultra-short WBI with SIB. * To assess overall survival (OS) in patients treated with ultra-short WBI with SIB.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
UW Carbone Cancer Center, Madison, Wisconsin, United States
Name: Jessica Schuster, MD
Affiliation: UW Carbone Cancer Center
Role: PRINCIPAL_INVESTIGATOR